Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 216

Similar articles for PubMed (Select 20306127)

1.

Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.

Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, van Gelder ME, Sieuwerts AM, Sleijfer S, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2011 Jan;125(2):387-94. doi: 10.1007/s10549-010-0836-9. Epub 2010 Mar 20.

PMID:
20306127
2.

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2009 Jul;116(2):263-71. doi: 10.1007/s10549-008-0125-z. Epub 2008 Jul 16.

PMID:
18629630
3.

TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.

Meijer D, Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, Foekens JA, Dorssers LC, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):253-60. doi: 10.1007/s10549-008-9934-3. Epub 2008 Feb 26.

PMID:
18299979
4.

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.

Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodríguez-González FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2012 Jun;133(3):937-47. doi: 10.1007/s10549-011-1877-4. Epub 2011 Nov 18.

5.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.

6.

Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.

van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-van Gelder ME, Klijn JG, Dorssers LC, Foekens JA.

J Natl Cancer Inst. 2000 Jan 19;92(2):120-7.

7.

Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.

Davies MP, Barraclough DL, Stewart C, Joyce KA, Eccles RM, Barraclough R, Rudland PS, Sibson DR.

Int J Cancer. 2008 Jul 1;123(1):85-8. doi: 10.1002/ijc.23479.

PMID:
18386815
8.

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R.

J Natl Cancer Inst. 2003 Mar 5;95(5):353-61.

9.

Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.

Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM.

Clin Cancer Res. 2008 Sep 1;14(17):5555-64. doi: 10.1158/1078-0432.CCR-08-0555.

10.

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):275-83. doi: 10.1007/s10549-008-9939-y. Epub 2008 Mar 4.

PMID:
18311582
11.

Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.

Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bièche I.

Clin Cancer Res. 2003 Apr;9(4):1259-66.

12.

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.

van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC.

J Clin Oncol. 2009 Feb 1;27(4):542-9. doi: 10.1200/JCO.2008.17.1462. Epub 2008 Dec 15.

13.

Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.

Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA.

Clin Cancer Res. 2004 Nov 15;10(22):7490-9.

14.

Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.

Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven T.

J Cell Physiol. 2011 Jul;226(7):1741-9. doi: 10.1002/jcp.22503.

PMID:
21506106
15.

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA.

Clin Cancer Res. 2003 Apr;9(4):1253-8.

16.

Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells.

Tu SH, Chang CC, Chen CS, Tam KW, Wang YJ, Lee CH, Lin HW, Cheng TC, Huang CS, Chu JS, Shih NY, Chen LC, Leu SJ, Ho YS, Wu CH.

Breast Cancer Res Treat. 2010 Jun;121(3):539-53. doi: 10.1007/s10549-009-0492-0. Epub 2009 Aug 5.

PMID:
19655245
17.

A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.

Rokavec M, Schroth W, Amaral SM, Fritz P, Antoniadou L, Glavac D, Simon W, Schwab M, Eichelbaum M, Brauch H.

Cancer Res. 2008 Dec 1;68(23):9799-808. doi: 10.1158/0008-5472.CAN-08-0247.

18.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
19.

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.

Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van Gelder ME, van Staveren IL, Klijn JG, Foekens JA, Berns EM.

J Clin Oncol. 2007 Feb 20;25(6):662-8.

20.

How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.

Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA.

Clin Cancer Res. 2005 Oct 15;11(20):7311-21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk